Fiona E. Craig

Fiona E. Craig

Auto-generated profile, based on publicly available information

Fiona E. Craig

Division of Hematopathology Mayo Clinic Arizona Phoenix Arizona USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2020 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
PHPedro Horna
Pedro Horna
SWSa A. Wang
Sa A. Wang
KWKristy L. Wolniak
Kristy L. Wolniak
KPKatherina Psarra
Katherina Psarra
JAJulia Almeida
Julia Almeida
RTRichard Torres
Richard Torres

1 April 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PHPedro Horna
Pedro Horna
MSMin Shi
Min Shi
DJDragan Jevremovic
Dragan Jevremovic
FCFiona E. Craig
Fiona E. Craig
NCNneka I. Comfere
Nneka I. Comfere
HOHoratiu Olteanu
Horatiu Olteanu

13 December 2018 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
ASAdam C. Seegmiller
Adam C. Seegmiller
EHEric D. Hsi
Eric D. Hsi
FCFiona E. Craig
Fiona E. Craig

15 July 2020 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
KLKirill A. Lyapichev
Kirill A. Lyapichev
IBIsmael Bah
Ismael Bah
AHAuris Huen
Auris Huen
MDMadeleine Duvic
Madeleine Duvic
MRMark J. Routbort
Mark J. Routbort
SWSa A. Wang
Sa A. Wang

21 May 2020 in Plastic Surgery
Verified
Journal Article
Open access
PDF file
TCTessa L. St. Cyr
Tessa L. St. Cyr
BPBarbara A. Pockaj
Barbara A. Pockaj
DNDonald W. Northfelt
Donald W. Northfelt
FCFiona E. Craig
Fiona E. Craig
MCMark W. Clemens
Mark W. Clemens
RMRaman C. Mahabir
Raman C. Mahabir
Worldwide, millions of women live with breast implants. Therefore, it is important that physicians be aware of an uncommon but possibly serious complication arising from breast implants: breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Breast implant–associated anaplastic large-cell lymphoma most commonly presents as a delayed fluid collection around a textured breast implant or as a mass in the capsule surrounding the implant. The exact pathogenesis of the disease remains unclear. The neoplastic cells of BIA-ALCL show strong uniform staining for CD30 and are consistently negative for activin receptor-like kinase 1. Patients with confirmed cases should be referred to a lymphoma specialist or breast medical oncologist for a complete oncologic evaluation before any surgical intervention. For disease confined to the fluid accumulation or capsule, or both, surgical removal of the implant and complete capsulectomy is the preferred treatment. Postoperative chemotherapy or radiation, or both, are not considered necessary for patients with limited-stage disease and are reserved for advanced disease stages. Generally, BIA-ALCL is a local disease that follows an indolent course and has an excellent prognosis. Although complete remission of disease has occurred in patients with BIA-ALCL, median overall survival is reduced. As of March 2018, approximately 529 unique, confirmed BIA-ALCL cases had been reported in 23 countries. To date, 16 patients have died from BIA-ALCL, and all had extracapsular involvement. The aim of this article is to summarize the diagnosis, evaluation, and management of BIA-ALCL, based on established guidelines, for all practitioners who may care for patients with breast implants.

28 October 2020 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
AIAndrea Illingworth
Andrea Illingworth
UJUlrika Johansson
Ulrika Johansson
SHShuguang Huang
Shuguang Huang
PHPedro Horna
Pedro Horna
SWSa A. Wang
Sa A. Wang
FCFiona E. Craig
Fiona E. Craig